Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
T3 Defense Inc (DFNS)
NYSEIndustrialsAerospace & DefenseSnapshot 2026-11-04
$2.29-19.65%
Close 2026-11-05 · 1-day change
NYSEIndustrialsAerospace & DefenseSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DFNS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash flow from operations improves from negative levels | A supporting condition in T3 Defense Inc's published investment case. The stated target is Cash flow from operations better than -$4.93M next 4 quarters. | Broken | Cash flow from operations falls below -$4.93M next 4 quarters | Cash from operations: $-4.864M FY2026-Q2; GAAP. Published target: Cash flow from operations better than -$4.93M next 4 quarters. Target period is not explicitly aligned with this observation. Jun 30, 2026-4,864,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth and acquisition story, not a proven durable compounder. The long-term thesis is in a watch state: revenue has risen from the first quarter, but recent financial performance remains weak and below its industry cohort.
The valuation evidence points to DFNS being cheap versus peers, but confidence in that comparison is low. The snapshot says only weak execution quality is reflected in current fragility, rather than a full mix of expensive valuation, weak execution, and turbulence; the expectations gap is therefore hard to judge.
Near-term results depend on execution against the reaffirmed 2026 revenue goal, while the available quarterly revenue figures do not establish that it will be met. Management has reported allied-market progress, including Rimon revenue and a European air-defense order, but the financial contribution from acquisitions is not yet clear; risk has also risen to high, and recent equity-related events add to the capital-allocation watchpoints.
The multi-year case hinges on whether acquisitions and expansion into allied defense markets produce measurable revenue and stronger execution. In the near term, a guidance cut would be a meaningful negative; continued earnings strength from industrial bellwethers could support the sector backdrop, while misses or lower guidance could remove that support.
Over the next 1 to 3 years, DFNS remains a high-risk thesis with early signs of market expansion but limited evidence that its strategy is translating into stronger financial performance. The key test is whether management can deliver on revenue and acquisition plans as sector conditions evolve. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stable management team including new CFO | A new CFO was hired recently to stabilize finances. | Intact | Unexpected key management departures or instability | 0 departures vs 0 allowed CFO transition noted as external hire; no unexpected key management departures or instability events detected. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves from large losses | T3 Defense aims to improve its operating income, which rose from -$25.27M to -$3.81M in early 2026. | Broken | Operating income falls below -$3.81M next 4 quarters | Operating income: $-3.378M FY2026-Q3; GAAP. Published target: Operating income better than -$3.81M next 4 quarters. Target period is not explicitly aligned with this observation. Oct 2, 2026-3,378,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches or exceeds $26M in FY26 | A primary condition in T3 Defense Inc's published investment case. The stated target is Revenue >= $26M in FY26. | Intact | Revenue falls below $26M in FY26 | Revenue: $3.996M FY2026-Q3; GAAP. Published target: Revenue >= $26M in FY26. Annual target cannot be compared with a quarterly or TTM observation. Oct 2, 20263,996,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.25 → $-3.21 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.25 | $33,430,000 | 1 / 2 |
| 2026-07-25 | $-6.25 | $33,430,000 | 1 / 2 |
| 2026-07-26 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-07-27 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-07-28 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-07-29 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-07-30 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-07-31 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-01 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-02 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-03 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-04 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-05 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-06 | $-6.14 | $33,430,000 | 1 / 2 |
| 2026-08-07 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-08 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-09 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-10 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-11 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-12 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-13 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-14 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-15 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-16 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-17 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-18 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-19 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-20 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-21 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-22 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-23 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-24 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-25 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-26 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-27 | $-7.27 | $33,430,000 | 1 / 2 |
| 2026-08-28 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-08-29 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-08-30 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-08-31 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-09-01 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-09-02 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-09-03 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-09-04 | $-5.09 | $33,430,000 | 1 / 2 |
| 2026-09-05 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-06 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-07 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-08 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-09 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-10 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-11 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-12 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-13 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-14 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-15 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-16 | $-4.71 | $33,430,000 | 1 / 2 |
| 2026-09-17 | $-4.86 | $33,430,000 | 1 / 2 |
| 2026-09-18 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-19 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-20 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-21 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-22 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-23 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-24 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-25 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-26 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-27 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-28 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-29 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-09-30 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-01 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-02 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-03 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-04 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-05 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-06 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-07 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-08 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-09 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-10 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-11 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-12 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-13 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-14 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-15 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-16 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-17 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-18 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-19 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-20 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-21 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-22 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-23 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-24 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-25 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-26 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-27 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-28 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-29 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-30 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-10-31 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-11-01 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-11-02 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-11-03 | $-3.21 | $31,810,000 | 1 / 2 |
| 2026-11-04 | $-3.21 | $31,810,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.